Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas Patients With Crohn’s Disease

Overview

Objectives: Primary: To demonstrate the safety of allogeneic UC-MSCs administered by injection for complex perianal fistulas in patients with Crohn's disease Secondary: To determine the efficacy of a single/multiple allogeneic UC-MSCs injection in improving complex perianal fistula complications and (re-epithelialization of the external openings).

Full Title of Study: “A Phase I Study of the Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) for Perianal Fistulas in Patients With Crohn’s Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2024

Detailed Description

Design and Investigation: Number of Patients: 5 (including a consideration of 20% [1 patient] dropout from the trial) Dosage and mode of administration Dosage: Two million cells per milliliter (2M/mL) with a total of 60 million PF2020-CELL (UC-MSCs) will be injected locally around the fistula tract, with a separation of 1 cm between injections. All patients will receive a total of 60 million cells per visit for 5 consecutive visits, with a 4-week interval between the injections. If the patient is completely healed during any course of stem cell injections, subsequent stem cell treatments can be discontinued. However, patients will still be required to undergo regular follow-up examinations, including physical examinations and other medical tests, until the study is completed. Mode of administration: The procedure involves localizing the fistulous tract, performing curettage and closing the internal opening, and the injection of PF2020-CELL (UC-MSCs). The indicated dose of PF2020-CELL (UC-MSCs) will be injected starting from the tissues around the internal orifice or orifices and then progressing towards the external opening.

Interventions

  • Biological: PF2020-CELL (UC-MSCs) – Allogeneic Human Umbilical Cord Mesenchymal Stem Cells
    • All patients will receive a total of 60 million PF2020-CELL (UC-MSCs) cells per treatment visit.

Arms, Groups and Cohorts

  • Experimental: PF2020-CELL (UC-MSCs) – Allogeneic Human Umbilical Cord Mesenchymal Stem Cells
    • Two million cells per milliliter (2M/mL) with a total of 60 million PF2020-CELL (UC-MSCs) will be injected locally around the fistula tract, with a separation of 1 cm between injections. All patients to receive allogeneic PF2020-CELL (UC-MSCs) via intralesional injection for 5 consecutive visits, with a 4-week interval between the injections. If the patient is completely healed during any course of stem cell injections, subsequent stem cell treatments can be discontinued. However, patients will still be required to undergo regular follow-up examinations, including physical examinations and other medical tests, until the study is completed.

Clinical Trial Outcome Measures

Primary Measures

  • No incidence of treatment-emergent adverse events (TEAEs)
    • Time Frame: Throughout study completion, an average of 1 year
    • TEAEs in this study are defined as adverse events other than: pyrexia (non-persistent fever, <38.5°C), anal abscess, pain in the rectum/anus & procedural pain (pain after fistula cleaning).

Secondary Measures

  • Clinical healing
    • Time Frame: Week 2, 6, 10, 14, 18, 20, 24, 32, 48
    • Mainly on re-epithelialization of external opening

Participating in This Clinical Trial

Inclusion Criteria

  • Adult men and women age 18 years and above. – Diagnosis of perianal fistulae associated with Crohn's disease refractory to medical therapy. – Presence of perianal fistula(s) with a maximum of 2 internal openings and a maximum of 3 external openings based on clinical assessment. – Fit for surgery. Exclusion Criteria:

  • Informed consent refusal. – Pregnancy or breastfeeding women. – Current diagnosis of active cancer or remission for less than 5 years. – Evidence of active sepsis or significant localised infection. – Patients with HIV, HBV, HCV or treponema infection, whether active or latent. – Patients with documented allergies. – Patients who have received infliximab or any other biologics in the 4 weeks before the cell treatment administration. – Patients currently receiving, or having received within 1 month prior to enrollment into this clinical trial, any investigational drug. – Patients with any other co-morbidity/ co-pathologies which is deemed as contraindication to stem cells infusion (infection, administration of steroids).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • CryoCord Sdn Bhd
  • Collaborator
    • University of Malaya
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • April Camilla Roslani, Prof. Dr., Principal Investigator, Faculty of Medicine, University of Malaya
  • Overall Contact(s)
    • April Camilla Roslani, Prof. Dr., +603-7949 2050, april@ummc.edu.my

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.